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Abstract
Glycosylation, the attachment of carbohydrates to proteins and lipids, influences many biological
processes. Despite detailed characterization of the cellular components that carry out
glycosylation, a complete picture of a cell’s glycoconjugates remains elusive because of the
challenges inherent in characterizing complex carbohydrates. This article reviews large-scale
techniques for accelerating progress in glycobiology.
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The problem with sugars
Glycobiology - the study of carbohydrates in biology - com-
bines expertise in synthetic and analytical chemistry and
carbohydrate biochemistry, as well as molecular and cellular
biology, to unravel the structural complexity, chemistry,
biosynthesis, and biological functions of sugar-bearing bio-
molecules. Over the past three decades, complex carbohy-
drates have become widely recognized as more than just an
energy source [1]. Indeed, glycosylation has been established
as a ubiquitous post-translational modification in higher
organisms that enables one protein (or lipid) to function as
many, and provides structural diversity that offers an expla-
nation for the unexpectedly low number of genes in the
human genome [2]. Complex sugars are major players in
numerous biological processes, including developmental
biology, the immune response and inflammatory disease,
cell proliferation and apoptosis, the pathogenesis of infec-
tious agents including prions, viruses, and bacteria, and a
wide range of diseases ranging from rare congenital disor-
ders to diabetes and cancer. 
The incredible complexity of a cell’s glycosylation machinery
and its final products, a vast array of oligosaccharides
(Figure 1), provides a research challenge in urgent need of
high-throughput, large-scale technologies. Unfortunately,
methods for studying and manipulating complex carbohy-
drates lag behind the tremendous advances made for nucleic
acids and proteins [3]. Progress has been sluggish, in part
because many biologists were slow to recognize the impor-
tance of sugars. But even when prescient researchers sought
to uncover the role of glycosylation they were often frus-
trated by the difficulty of characterizing carbohydrates and
the near impossibility of manipulating them with precision
in living cells. In this article, we give a brief overview of the
overriding factor hindering glycobiology - the incredible
complexity of carbohydrates - before describing current
technologies available for studying glycosylation and con-
cluding with a guarded, but optimistic, prediction that glyco-
biology will catch up with other areas of biochemistry and
molecular biology largely by virtue of promising large-scale
technologies that are now on the horizon.
Unraveling the biosynthetic glycosylation
machinery 
Although many recent developments in ‘glycomics’ focus on
structural and functional analysis of surface-displayed
sugars, the biosynthetic machinery that builds these
complex molecules also greatly interests the glycobiologist.
We briefly discuss carbohydrate biosynthesis here, both to
acknowledge the heroic researchers who laid an impressive
foundation without benefit of large-scale technologies and to
illustrate the need for high-throughput strategies to acceler-
ate progress. We use the term glycosylation machinery to236.2 Genome Biology 2005, Volume 6, Issue 11, Article 236 Campbell and Yarema http://genomebiology.com/2005/6/11/236
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Figure 1 (see legend on the following page)
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6 Cell-surfacedescribe biochemical pathways that convert monosaccha-
rides (for example, dietary glucosamine) into nine different
high-energy sugar-nucleotide building blocks (for example,
UDP-N-acetylglucosamine (UDP-GlcNAc)) and assemble
them into the complex oligosaccharides found on proteins and
lipids (Figure 1). Basic components of this metabolic factory
were discovered in a painstakingly slow, one-at-a-time process
over many decades (for a detailed perspective, see the fasci-
nating historical overview by Saul Roseman [3]). Traditional
biochemical studies from the 1950s to the 1970s identified
many small-molecule metabolites and characterized the enzy-
matic activities that link them into metabolic pathways. Once
metabolites were arranged into putative pathways, the next
requirement was to match genes with enzymatic activities; this
formidable task was tackled, primarily one gene at a time, by
elegant but time-consuming methods such as the forward
genetic screens developed in the 1970s, and by the DNA
cloning and recombinant gene expression strategies that
became routine in the 1980s [4]. More recently, RNA-inhibi-
tion techniques have begun to yield insights into glycosylation
by downregulating individual genes [5].
Around 2% of human genes are involved in glycosylation, as
judged from the most recent developments in large-scale
biology, primarily the sequencing of the human genome
coupled with predictive algorithms for gene function. This
information, along with ‘metabolomic’ methods for large-
scale characterization of small-molecule metabolites [6], has
sped up the placement of the finishing touches on the frame-
work of the glycosylation machinery. Almost all its metabolic
components are known and have been assembled into well
defined pathways, as can be seen by following the links for
‘Carbohydrate metabolism’ and ‘Glycan biosynthesis and
metabolism’ in the Kyoto Encyclopedia of Genes and
Genomes, KEGG [7]. A static picture of glycosylation does
not, however, reflect dynamic moment-by-moment, devel-
opmental, and disease-related metabolic fluctuations, nor
does it provide much insight into subcellular organization
and organelle topography, which are critical factors in
shaping final oligosaccharide structures [8]. In the future,
computational ‘systems biology’ promises to bring the glyco-
sylation machinery to life [9] and thereby offers insights into
repairing glycosylation abnormalities associated with wide-
spread diseases, including diabetes [5] and cancer [10].
Carbohydrate characterization
Structures of sugars have long fascinated chemists and biol-
ogists, beginning with Emil Fischer’s landmark efforts to
decipher the isoforms of hexoses more than a century ago
[11]. Since then, even with modern techniques, biologists
have been outpaced by the difficulty of obtaining a glycosyla-
tion profile - the specific complement of glycoconjugates
present - of even a single cell. To illustrate that there is no
simple task in carbohydrate analysis, Figure 1 shows a few
biologically significant glycoconjugates. Even the addition of
a single N-acetylglucosamine moiety to a protein to give the
O-GlcNAc modification, which regulates numerous bio-
chemical pathways by acting in a yin-yang manner with
phosphorylation [12] (Figure 1c), is complicated by its occur-
rence on hundreds of different cytosolic and nuclear pro-
teins, and on multiple sites within a single protein. The
various biological activities of glycosphingolipids, relatively
simple sugar-bearing biomolecules exemplified by the gan-
glioside GM3 (Figure 1d), demonstrate that very subtle
changes to sialic acid (N-acetylneuraminic acid or Sia), an
unusual nine-carbon sugar found in more than 50 different
chemically distinct forms [13], can regulate apoptosis, senes-
cence, and proliferation, thereby highlighting the need for
careful analysis of fine structural details. 
Moving to larger glycoconjugates, prions are glycosylated
proteins that possess only two sites where oligosaccharides
attach (Figure 1a). Even so, any one of several dozen differ-
ent sugar chains can reside at either site; consequently,
prions exist as hundreds of distinct entities. The discovery of
the influence of carbohydrates on prion infectivity and on
the development of spongiform encephalopathies [14,15]
underlines the importance of fully defining structural het-
erogeneity of this kind. As a final example, the heavily glyco-
sylated cell-surface glycoprotein CD34 (Figure 1a), found on
hematopoietic cells and epithelial cells, serves as a develop-
mental marker for hematopoietic cells, mediates leukocyte
homing, and contributes to cancer metastasis. It bears 20 or
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Figure 1 (see legend on the previous page)
Systems and molecular complexity in glycobiology. (a) The glycosylation machinery consists of an intricate network of metabolic pathways that
interconvert monosaccharides and produce high-energy sugar nucleotides (full details of the pathways are available in [9]). The hexosamine pathway [46]
that converts glucosamine (1) to UDP-N-acetylglucosamine (UDP-GlcNAc) (2) is highlighted in blue. The versatility of the glycosylation machinery is
epitomized by the conversion of UDP-GlcNAc into N-acetylmannosamine (ManNAc) (3), a sugar that is metabolically converted to CMP-sialic acid
(CMP-Sia; 4) by the pathway highlighted in red. UDP-GlcNAc and CMP-Sia, together with seven other sugar nucleotides, are transported into the
endoplasmic reticulum (ER) and Golgi apparatus (5), where they are used for the production of complex oligosaccharides (6) that comprise the
glycosylation profile of the cell surface. This profile is made up of proteins (such as the prion protein and CD34, shown here) and glycolipids such as
ganglioside GM3, a glycosphingolipid. Sialic acid (Sia) is a ubiquitous terminal modification. (b) The chemical structures of glucosamine, UDP-GlcNAc,
UDP-ManNAc, and CMP-Sia. (c) As well as being used to build complex oligosaccharides, UDP-GlcNAc is a high-energy building block that provides the
GlcNAc residue required for O-GlcNAc protein modification in the cytosol [13]. (d) Slight modifications to the chemical structure of CMP-Sia elicit
profound changes in biological activity. The membrane glycosphingolipid ganglioside GM3 (center) is converted to pro-apoptotic gangliosides GD3 by
addition of Sia (top), whereas deacetylation of GM3 yields de-N-acetyl GM3, which has a growth stimulatory effect.more separate oligosaccharide chains [16], implying that, if
ten different oligosaccharide structures randomly occur at
each site (a conservative estimate), 1020 different forms of
CD34 can exist and each of the approximately 104 to 105
copies of this protein found in a typical cell has a reasonable
probability of being unique. 
Conventional glycosylation profiling
Only recently has methodology advanced sufficiently to
obtain complete glycosylation profiles of glycoconjugates
such as prions or CD34 (Figure 2). To briefly summarize
today’s technology, a plethora of mass spectrometry (MS)
methods are becoming affordable and user-friendly [17,18],
pulsed-amperometric detection methodology is making the
separation of carbohydrates by high-pressure liquid chro-
matography (HPLC) attractive, increasingly sensitive
nuclear magnetic resonance (NMR) technology is allowing
this powerful technique of structure determination and iden-
tification to be applied to glycoconjugates isolated from
natural sources, and lectins are finding new uses as detec-
tion agents for carbohydrates in chromatography and
protein arrays [19-21]. Excellent reviews provide a detailed
picture of how different methodologies are coalescing into a
powerful set of tools for sophisticated and highly sensitive
investigation of glycoconjugates [22,23].
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Figure 2
Conventional low-throughput glycoconjugate characterization and steps that will improve throughput. Current strategies for oligosaccharide
identification include multiple time-consuming steps including, but not limited to, (1) isolation of individual glycoconjugates, such as prions or CD34 (see
Figure 1), from a cell or tissue; (2) the detachment and purification of each oligosaccharide from a particular glycoconjugate; and (3) a one-at-a-time
structural characterization and identification. Each of these steps currently requires multiple procedures and method of analysis [21], as illustrated in the
boxes for steps (1) and (3). Streamlined methods now under development, such as (4) the coupling of isolation by glycoblotting with identification by
mass spectrometry (MS) [35], and automated interpretation of spectra [30], are also shown. These methods, along with array-based technologies (see
Figure 3), offer hope for high-throughput glycan characterization in the near future.
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4While the isolation and characterization of highly complex
glycoproteins are impressive feats, the sobering reality is
that only a handful of the thousands of different glycoconju-
gates in the human body have been analyzed so far, which
leaves the enormous carbohydrate diversity of even a single
cell unknown in molecular detail. To further complicate
matters, glycosylation profiles are not static, but rapidly
change as cells differentiate, undergo apoptosis, or become
diseased. Today’s technologies are inadequate for determin-
ing the dynamic glycosylation profile of a cell and fall well
short of the ultimate goal of glycomics - the evaluation of an
entire organism. To dispel the gloom, however, underlying
technologies for innovative, large-scale glycomic techniques
are developing rapidly - both by bringing new techniques to
carbohydrate analysis and by refining established methods
to increase throughput. These two approaches, exemplified
by array-based technologies and the automation of mass
spectrometry, respectively, are discussed below.
Development of high-throughput technologies
for glycomics
The success of DNA microarrays, on which thousands of dis-
crete interactions are observed at once, has spawned array-
based methods for confronting almost every problem.
Carbohydrate analysis is no exception, and two array-based
strategies are now being pursued. The more mature approach
- which has reached the point of using robotic microspotting -
involves attaching hundreds of different oligosaccharides of
known composition to a surface, and is used to identify
binding partners (Figure 3) [24-26]. This approach repro-
duces the ‘glycocode’ found on the cell surface and helps
determine how biological systems decode the vast informa-
tion-carrying capacity of carbohydrates [27]. In a second type
of array, carbohydrate-binding proteins such as lectins are
arrayed on the surface. This technique, made possible by
protein-array printing techniques that avoid altering the
recognition capacity of proteins, has recently been demon-
strated in concept for a modestly sized lectin array [20]. In
the future, when the hundreds of lectins now available, as
well as the growing number of antibodies that bind specific
glycan structures, are incorporated, such arrays will facilitate
the rapid profiling of cellular glycosylation states. 
Conventional methods, including chromatography or two-
dimensional gel electrophoresis, used in proteomics to sepa-
rate proteins isolated from a cell or tissue (Figure 2), are
rapidly and effectively being adapted for oligosaccharide
characterization [28]. In contrast to microarrays, identifica-
tion is not inherent in these techniques, necessitating a
reliance on mass spectrometry for identification of glycocon-
jugates after separation; mass spectrometry is extremely sen-
sitive, allowing minute amounts of samples isolated from
biological samples or purified by capillary electrophoresis or
two-dimensional gels to be identified successfully [29].
Unfortunately, the need to isolate individual oligosaccharides
by chromatography or electrophoresis prior to mass spec-
trometry, and the lack of automated identification algo-
rithms, limits the throughput of these methods, leading to
techniques such as fluorescence differential gel elec-
trophoresis (DIGE [30]), that do not characterize all prod-
ucts and settle for the less ambitious goal of identifying a
limited number of molecules that differ between two
samples (for example, healthy versus diseased tissue) [31].
To overcome the bottleneck of identification, much effort is
being put into developing automated, high-throughput com-
putational tools for the interpretation of glycoconjugate
mass spectra [23,32].
Chemistry and glycomics
Chemical tools have been vitally important for the develop-
ment of large-scale glycomics. These range from automated
synthesis [33] to development of chemoselective coupling
reactions [34] that facilitate attachment of oligosaccharides to
arrays [35,36] and underlie high-sensitivity methods for iso-
lating sugars from biological extracts [29,37]. Another increas-
ingly important contribution of chemists is the synthesis of
abiotic monosaccharide analogs that are used in oligosaccha-
ride-engineering strategies based on metabolic substrates.
This approach exploits the unusual permissiveness of certain
biochemical pathways involved in carbohydrate biosynthesis
to accommodate non-natural metabolic intermediates [38].
By intercepting a targeted pathway with an analog, it is possi-
ble to install abiotic, chemically distinct sugars into mature
glycoconjugates. The incorporation of azide-modified analogs
of sialic acid into the B-lymphocyte surface glycoprotein
CD22, an important modulator of B-lymphocyte activity, pro-
vided a recent example of this technique’s ability to discover
new insights into biological roles of glycosylation: photoaffin-
ity cross-linking of the azide-modified sialic acid allowed in
situ identification of a potentially important modulator of
B-cell activity - previously unappreciated homomeric binding
among neighboring CD22 molecules [39].
An adaptation of the tagging-via-substrate (TAS) proteomics
approach [40] is now transforming metabolic oligosaccha-
ride engineering into a high-throughput technology. TAS
technology involves the biosynthetic incorporation of an
azide functional group into the design of a basic building
block such as an amino acid [40] or monosaccharide [41],
followed by isolation of labeled biomolecules via this chemi-
cal tag. In a pioneering study, N-azidoacetylglucosamine, an
analog of GlcNAc, was used to tag O-GlcNAc-labeled pro-
teins [42]. The subsequent identification of around 25
O-GlcNAc-modified proteins in the brain established a bio-
chemical link between O-GlcNAc modification and neuronal
signaling, synaptic plasticity, and gene expression [43]. Of
equal importance, this study provides a precedent for
expanding the TAS strategy to other tissues and for applying
it to uncover subtle metabolic differences between healthy
and diseased cells. 
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In conclusion, the hope for an increased pace of discovery in
glycobiology, where progress has lagged because “carbohy-
drates are complex” [3], lies in several large-scale technolo-
gies now in the early stages of development. Continued
progress is not without its problems. For example, the
current versions of arrays contain only a very small fraction
of all the carbohydrates found in nature [33]. A second issue
is that the exact presentation of oligosaccharides is often
important to achieve the ‘cluster glycoside effect’, whereby
carbohydrate-binding interactions are specified by multiple
simultaneous interactions that achieve both specificity and
236.6 Genome Biology 2005, Volume 6, Issue 11, Article 236 Campbell and Yarema http://genomebiology.com/2005/6/11/236
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Figure 3
Oligosaccharide and carbohydrate-binding protein arrays. (a) Oligosaccharide microarrays are used to detect and characterize carbohydrate-binding
proteins. They are constructed by (1) spotting known oligosaccharides (either synthetic or naturally isolated) onto a solid surface such as a treated glass
slide in a predetermined array. Whole cells can be bound to the array (2), but it is more common to first fractionate cells or tissues to isolate (3)
putative carbohydrate-binding proteins. (b) Arrays of known carbohydrate-binding proteins (either lectins or monoclonal antibodies) are used to detect
and characterize oligosaccharides. They are produced by printing spots of the proteins onto a suitable surface (1). Again, whole cells (2) can be bound to
the array, but more usually (3) their cell-surface oligosaccharides will be isolated and used. Both types of array can be used for a variety of purposes. 
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3avidity [44,45]. Today’s methods of attaching carbohydrates
to an array, whereby they are spotted onto inflexible flat sur-
faces that have very different biophysical properties from the
flexible peptide backbone of, say, CD34 (Figure 1a) or the
spherical geometry of highly branched dendrimers [46], are
unlikely to faithfully reproduce physiological binding.
Other nascent high-throughput methods, such as the
automation of mass spectrometry, must also overcome sig-
nificant barriers. The use of mass spectrometry in glycomics,
for instance, is hampered in various ways: glycan databases
are incomplete; that is, many of the oligosaccharides found
in nature have not yet been isolated and characterized by
mass spectrometry; the structural complexity of oligosaccha-
rides limits current identification algorithms to structures of
less than ten monosaccharides; and the identification of the
correct oligosaccharide from many isomeric options remains
a challenge [32]. Mass spectrometry must also overcome its
aversion to sialic acids. In the past, this structurally diverse
[12], negatively charged sugar has typically been removed to
simplify analysis; the critical role of sialic acid in modulating
the bioactivity of GM3 (Figure 1e) is but one of numerous
examples that insist that this sugar cannot continue to be
ignored. To end optimistically, these challenges, although
appearing daunting today, will be overcome in the near
future - within two to three years in one prediction [33] - if
scientific curiosity and the potential multibillion dollar
market for therapeutic glycoproteins continue to accelerate
the current pace of technological development.
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